Quantitative Bridge or Black Box? A Practice-Based Framework for Statistical Programming Contributions to Population Pharmacokinetic/ Pharmacodynamic Modeling in Regulatory Drug Development

Population pharmacokinetic/pharmacodynamic (PK/PD) modeling now sits at the center of model-informed drug development (MIDD), shaping dose selection, labeling language, and regulatory submissions across therapeutic areas. Less attention goes to the statistical and clinical programmers who build the analysis-ready datasets. These models depend on a role distinct from the pharmacometrician who fits the model itself. This article proposes a four-domain framework for describing that contribution: noncompartmental analysis (NCA) dataset construction and quality control;population PK datasetand diagnostic-output support; exposure-response and dose-selection analysis support; and specialized regulatory analysesspanning drug-drug interaction, bioequivalence, and pediatric extrapolation studies. Drawing on FDA and CDISC guidance, implementation standards, and pharmacometrics practice literature, the synthesis characterizes the technical demands, regulatory touchpoints, and quality-control conventions specific to each domain. Programmer contribution turns out to escalate unevenly rather than proportionally across domains: dataset-construction choices especially around below-limit-of-quantification handling and covariate dataset structure carry direct downstream weight on model validity and labeling claims, and this weight increases sharply once analyses move into specialized regulatory territory. With FDA’s PDUFA VII commitments extending MIDD infrastructure through fiscal years 2023 to 2027, the framework gives a vocabulary for a programming specialization that current workforce literature treats as undersupplied relative to demand,with direct bearingon training pathways and staffing models for regulatory-facing quantitative pharmacology teams.